Low doses of amphetamine-like stimulants exert arousal- and attention-enhancing actions. The ability of stimulants to enhance alert waking has long-been exploited and is a contributing factor to the widespread illicit use of these drugs. Additionally, these drugs are used widely in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. The neurochemical mechanisms subserving the behavioral effects of moderate-to-high doses of these drugs have been examined intensively. Neurochemically, these drugs increase synaptic concentrations of dopamine (DA) and norepinephrine (NE). Evidence indicates that actions of DA within the striatum and nucleus accumbens are critical components of the rewarding and locomotor activating effects of stimulants. The rewarding effects of these drugs are superimposed upon an alert behavioral state (e.g. prolonged periods of waking/enhanced alertness). Previous studies by the PI demonstrate potent actions of the locus coeruleus-noradrenergic system on EEG and behavioral indices of waking via actions of beta-and alpha1 -receptors located within the medial basal forebrain. Additionally, the PI has demonstrated that amphetamine acts within the same basal forebrain regions to exert arousal-enhancing (wake-promoting) actions. Recent studies also suggest arousal-enhancing actions of DA. The PI has initiated a research program that assesses the contribution of NE and DA to the arousal-enhancing actions of stimulants and identifies the neurocircuitry underlying these actions. Recent studies demonstrate potent arousal-enhancing actions of the peptides, hypocretins. Dysregulation of hypocretin neurotransmission appears to be an etiological factor in the arousal disorder, narcolepsy. Stimulants elicit an activation of hypocretin neurons, suggesting the participation of hypocretins in at least a subset of the behavioral actions of these drugs, including their therapeutic action in the treatment of narcolepsy. Utilizing a combination of behavioral, pharmacological, and anatomical methods, the proposed studies will provide novel information concerning the degree to which NE, DA and hypocretins participate in the behavioral effects of. Information obtained in these studies may provide insight into mechanisms underlying, and future treatment of, stimulant drug abuse, ADHD and narcolepsy.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Scientist Development Award - Research (K02)
Project #
5K02DA000389-10
Application #
7391579
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Frankenheim, Jerry
Project Start
1999-05-10
Project End
2009-03-31
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
10
Fiscal Year
2008
Total Cost
$134,622
Indirect Cost
Name
University of Wisconsin Madison
Department
Psychology
Type
Schools of Arts and Sciences
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Jordan, Chloe J; Xi, Zheng-Xiong (2018) Discovery and development of varenicline for smoking cessation. Expert Opin Drug Discov 13:671-683
Zou, Mu-Fa; Cao, Jianjing; Abramyan, Ara M et al. (2017) Structure-Activity Relationship Studies on a Series of 3?-[Bis(4-fluorophenyl)methoxy]tropanes and 3?-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders. J Med Chem 60:10172-10187
Yang, Hong-Ju; Zhang, Hai-Ying; Bi, Guo-Hua et al. (2017) Deletion of Type 2 Metabotropic Glutamate Receptor Decreases Sensitivity to Cocaine Reward in Rats. Cell Rep 20:319-332
España, Rodrigo A; Schmeichel, Brooke E; Berridge, Craig W (2016) Norepinephrine at the nexus of arousal, motivation and relapse. Brain Res 1641:207-16
Sandtner, Walter; Stockner, Thomas; Hasenhuetl, Peter S et al. (2016) Binding Mode Selection Determines the Action of Ecstasy Homologs at Monoamine Transporters. Mol Pharmacol 89:165-75
Spencer, Robert C; Devilbiss, David M; Berridge, Craig W (2015) The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex. Biol Psychiatry 77:940-50
Schmeichel, Brooke E; Berridge, Craig W (2014) Amphetamine acts within the lateral hypothalamic area to elicit affectively neutral arousal and reinstate drug-seeking. Int J Neuropsychopharmacol 17:63-75
Schmeichel, Brooke E; Berridge, Craig W (2013) Wake-promoting actions of noradrenergic ?1 - and ?-receptors within the lateral hypothalamic area. Eur J Neurosci 37:891-900
Schmeichel, Brooke E; Zemlan, Frank P; Berridge, Craig W (2013) A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder. Neuropharmacology 64:321-8
Berridge, Craig W; Schmeichel, Brooke E; España, Rodrigo A (2012) Noradrenergic modulation of wakefulness/arousal. Sleep Med Rev 16:187-97

Showing the most recent 10 out of 22 publications